Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease

Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease

<p dir="ltr">Accumulation of α-synuclein into toxic oligomers or fibrils is implicated in dopaminergic neurodegeneration in Parkinson’s disease. Here we performed a high-throughput, proteome-wide peptide screen to identify protein-protein interaction inhibitors that reduce α-synuclei...

Full description

Saved in:
Bibliographic Details
Main Author: Satra Nim (11540447) (author)
Other Authors: Darren M. O’Hara (9201761) (author), Carles Corbi-Verge (527968) (author), Albert Perez-Riba (5004785) (author), Kazuko Fujisawa (11692038) (author), Minesh Kapadia (582056) (author), Hien Chau (355945) (author), Federica Albanese (19482364) (author), Grishma Pawar (10666899) (author), Mitchell L. De Snoo (19482367) (author), Sophie G. Ngana (19482370) (author), Jisun Kim (837555) (author), Omar M. A. El-Agnaf (8809331) (author), Enrico Rennella (2083291) (author), Lewis E. Kay (135973) (author), Suneil K. Kalia (9201773) (author), Lorraine V. Kalia (9201770) (author), Philip M. Kim (11540462) (author)
Published: 2023
Subjects:
Biomedical and clinical sciences
Clinical sciences
Neurosciences
Pharmacology and pharmaceutical sciences
α-Synuclein
Parkinson’s Disease
Toxic Oligomers
Protein-Protein Interaction Inhibitors
CHarged Multivesicular body Protein 2B (CHMP2B)
Preclinical Models
C. elegans
Rat Models
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items